Physician profile
Anna Roshal
NPI 1124081799
$14,742.65
in general payments reported to CMS, 2019-2025
22 companies · $7,282 in 2025
The $7,282 reported for 2025 was more than what 86% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $53.32 · 2021: $1,610 · 2023: $5,423 · 2024: $91.69 · 2025: $7,282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,150 · Travel and Lodging: $3,350 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,500 · Food and Beverage: $369 · Honoraria: $360 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,150.00 |
| Travel and Lodging | $3,349.71 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,500.00 |
| Food and Beverage | $369.00 |
| Honoraria | $360.00 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,097.49 | 2023-2025 | Tagrisso, Imfinzi |
| Avyxa Pharma, LLC | $3,893.99 | 2025 | |
| Emd Serono, INC. | $2,834.16 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $1,260.00 | 2021 | |
| Deciphera Pharmaceuticals INC. | $500.00 | 2025 | Romvimza |
| Daiichi Sankyo INC. | $360.00 | 2023 | |
| Janssen Scientific Affairs, LLC | $350.00 | 2021 | |
| Genentech USA, INC. | $92.70 | 2019-2020 | |
| Amgen INC. | $78.02 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $44.31 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $43.67 | 2019-2024 | Opdualag |
| Tempus Ai, INC | $33.47 | 2024 | |
| Pharmacosmos Therapeutics INC. | $24.65 | 2024 | Monoferric |
| Array Biopharma INC | $22.64 | 2019 | |
| Astellas Pharma US INC | $20.36 | 2023 | Xospata |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $19.58 | 2019 | |
| Incyte Corporation | $16.42 | 2019 | |
| Eisai INC. | $15.29 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $13.67 | 2023 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $11.21 | 2019 | |
| Janssen Biotech, INC. | $11.02 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Roshal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.